Acute Lymphoblastic Leukemia(T-ALL)-08

Yesheng wekuFujian akati, "Dai ndakaziva nezveCAR-T kuLudaopei, ndingadai ndakakurumidza kuuya."

MunaGunyana 2017, Yesheng akagadzira mapundu kumeso, ayo akapararira zvishoma nezvishoma uye akabatanidzwa kuita zvigamba. Pakazosvika Kukadzi 28, 2018, kuongororwa kwemwongo wemapfupa kwakasimbisa "acute T-cell lymphoblastic leukemia" mushure memakosi mazhinji echemotherapy, paine macheki akasara asina kunaka. Mishonga yese yakamiswa muna Chikumi 2019.

Muna Chivabvu 2021, Yesheng akaunzwa nemazhinji munharaunda yemuromo-pharyngeal uye akawedzera mutsipa lymph nodes. Kuongororwazve kwemwongo wemapfupa kwakasimbisa kudzoka zvachose kweleukemia. Musi waMay 28, Yesheng akaendeswa kuChipiri Hematology Dhipatimendi reLudaopei Hospital kuti apiwe. Mushure mekuongororwa kwakadzama, kuongororwa kwakadzokororwa ku "acute leukemia (T/myeloid biphenotypic)."

Imwe kutenderera kwechemotherapy haina kuita kuti kuregererwa mumwongo wepfupa. Musi waChikunguru 27, Yesheng akagamuchira CD7 CAR-T cell infusion, ichiteverwa nechemotherapy yakasanganiswa ne autologous CD7 CAR-T cell therapy. Mazuva gumi nemashanu mushure mekuiswa, kuongororwa kwemwongo wepfupa kwakaratidza kusara kwechirwere chisina kunaka, negiredhi 1 cytokine release syndrome (CRS) maitiro uye pasina central nervous system adverse reactions.